Dermapharm Holding SE
DMPHFOTCHealthcare● Active
$59.00
+$19.44(+49.14%)
Market Cap$2.9B
P/E Ratio—
52W High$59
52W Low$39.56
Dermapharm Holding SE (DMPHF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DMPHF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
$0.97
Est. $0.97 · +0.0%
Revenue
$0.35B
Est. $0.28B · +26.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
DMPHF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.40
Rev. $5.46B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.40
Rev. Est.$5.46B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 25, 2026 | — | — | — | — | $0.33B | — |
| — Q2 FY2026 | May 13, 2026 | $0.97 | $0.97 | +0.0% | $0.35B | $0.28B | +26.1% |
| ▲ Q1 FY2026 | Mar 10, 2026 | $0.48 | $0.85 | +75.7% | $0.35B | $0.35B | -0.0% |
| — Q3 FY2025 | Aug 26, 2025 | — | $0.46 | — | $0.32B | $0.32B | -0.0% |
| — Q2 FY2025 | May 15, 2025 | — | $0.68 | — | $0.33B | — | — |
| — Q1 FY2025 | Mar 14, 2025 | — | $0.39 | — | $0.30B | $0.31B | -1.5% |
| — Q4 FY2024 | Nov 14, 2024 | — | $0.66 | — | $0.34B | $0.33B | +3.6% |
| — Q3 FY2024 | Aug 14, 2024 | — | $0.34 | — | $0.31B | $0.30B | +1.8% |
Q3 FY2026
Aug 25, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026
EPS Actual
$0.97
EPS Est.
$0.97
EPS Surpr.
+0.0%
Revenue
$0.35B
Q1 FY2026
Mar 10, 2026Beat
EPS Actual
$0.85
EPS Est.
$0.48
EPS Surpr.
+75.7%
Revenue
$0.35B
Q3 FY2025
Aug 26, 2025
EPS Actual
$0.46
EPS Est.
—
EPS Surpr.
—
Revenue
$0.32B
Q2 FY2025
May 15, 2025
EPS Actual
$0.68
EPS Est.
—
EPS Surpr.
—
Revenue
$0.33B
Q1 FY2025
Mar 14, 2025
EPS Actual
$0.39
EPS Est.
—
EPS Surpr.
—
Revenue
$0.30B
Q4 FY2024
Nov 14, 2024
EPS Actual
$0.66
EPS Est.
—
EPS Surpr.
—
Revenue
$0.34B
Q3 FY2024
Aug 14, 2024
EPS Actual
$0.34
EPS Est.
—
EPS Surpr.
—
Revenue
$0.31B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $0.84 | $0.84 | $0.84 | 1 |
| Q4 FY2025 | $0.41 | $0.41 | $0.41 | 1 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.3B | $0.3B | $0.3B | 1 |
| Q3 FY2026 | $0.3B | $0.3B | $0.3B | 1 |
| Q2 FY2026 | $0.3B | $0.3B | $0.3B | 1 |
| Q1 FY2026 | $0.3B | $0.3B | $0.3B | 1 |
| Q4 FY2025 | $0.3B | $0.3B | $0.3B | 1 |
| Q3 FY2025 | $0.3B | $0.3B | $0.3B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +0.0% | $39.56 | $39.56 | +0.00% |
| ▲ Q1 FY2026 | Mar 10, 2026 | +75.7% | $39.56 | $39.56 | +0.00% |
| — Q3 FY2025 | Aug 26, 2025 | — | $39.56 | $39.56 | +0.00% |
| — Q2 FY2025 | May 15, 2025 | — | $39.56 | $39.56 | +0.00% |
| — Q1 FY2025 | Mar 14, 2025 | — | $42.68 | $42.68 | +0.00% |
| — Q4 FY2024 | Nov 14, 2024 | — | $42.68 | $42.68 | +0.00% |
| — Q3 FY2024 | Aug 14, 2024 | — | $42.68 | $42.68 | +0.00% |
| — Q2 FY2024 | May 15, 2024 | — | $42.68 | $42.68 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 13, 2026
EPS Beat/Miss
+0.0%
Price Before
$39.56
Price After
$39.56
Q1 FY2026+0.00%
Report Date
Mar 10, 2026
EPS Beat/Miss
+75.7%
Price Before
$39.56
Price After
$39.56
Q3 FY2025+0.00%
Report Date
Aug 26, 2025
EPS Beat/Miss
—
Price Before
$39.56
Price After
$39.56
Q2 FY2025+0.00%
Report Date
May 15, 2025
EPS Beat/Miss
—
Price Before
$39.56
Price After
$39.56
Q1 FY2025+0.00%
Report Date
Mar 14, 2025
EPS Beat/Miss
—
Price Before
$42.68
Price After
$42.68
Q4 FY2024+0.00%
Report Date
Nov 14, 2024
EPS Beat/Miss
—
Price Before
$42.68
Price After
$42.68
Q3 FY2024+0.00%
Report Date
Aug 14, 2024
EPS Beat/Miss
—
Price Before
$42.68
Price After
$42.68
Q2 FY2024+0.00%
Report Date
May 15, 2024
EPS Beat/Miss
—
Price Before
$42.68
Price After
$42.68
Avg Beat Reaction+0.00%
Beat Rate2 / 8 quarters
Largest Move+0.00% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DMPHF ends December
Dermapharm Holding SE (DMPHF) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $0.97 (in line with the analyst consensus of $0.97). DMPHF has beaten EPS estimates for 2 consecutive quarters. The next DMPHF earnings date is expected around September 1, 2026.
Each quarter, investors track DMPHF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DMPHF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DMPHF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DMPHF earnings · 4 questionsDermapharm Holding SE's next earnings report is expected around September 1, 2026. DMPHF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DMPHF historically reports after market close (AMC).
DMPHF earnings datewhen is DMPHF earningsDMPHF next earnings datewhen does DMPHF report earningsDMPHF earnings calendar
▸ Source: FMP · Dermapharm Holding SE SEC filings · US GAAP · Dermapharm Holding SE SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026